Treat-to-target and treat-to-budget in rheumatoid arthritis: Measuring the value of Individual therapeutic interventions

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Sacristán, José A.
dc.contributor.author Díaz, Silvia
dc.contributor.author Torre, Inmaculada de
dc.contributor.author Inciarte-Mundo, José
dc.contributor.author Balsa, Alejandro
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) es_ES
dc.date.accessioned 2020-09-18T08:07:18Z
dc.date.available 2020-09-18T08:07:18Z
dc.date.issued 2019-10-30
dc.identifier.citation Rheumatology and Therapy 6 (2019): 473–477 en_US
dc.identifier.issn 2198-6584 es_ES
dc.identifier.uri http://hdl.handle.net/10486/691951
dc.description.abstract Treat-to-target (T2T) and dose tapering after obtaining the therapeutic objective (called “treat-to-budget”-T2B-in this Commentary) are the two most commonly used therapeutic strategies in rheumatoid arthritis. In theory, both strategies could add value to the healthcare system, although they are focused on different objectives: T2T strategy improves outcomes but increases short-term costs, while the cost savings obtained through T2B are associated with higher relapse rates. The systematic implementation of both strategies must be founded on solid evidence of their effectiveness and efficiency. However, the level of evidence between guidelines and individual studies is inconsistent for both strategies and the number and the quality of cost-effectiveness analyses is scarce. Raising the level of evidence requires a move from generalization to individualization by conducting randomized clinical trials that assess each of the many strategies that fall under the umbrella of the overall T2T and T2B concepts. In addition, such studies should consider the therapeutic goals and impact of the disease from the perspective of individual patients, which is only possible by promoting shared decision-making en_US
dc.description.sponsorship Fee were funded by Lilly Spain en_US
dc.format.extent 5 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng es_ES
dc.publisher Springer (part of Springer Nature) en_US
dc.relation.ispartof Rheumatology and Therapy en_US
dc.rights © 2019 The Author(s) en_US
dc.subject.other DMARDs en_US
dc.subject.other Rheumatoid arthritis en_US
dc.subject.other Tapering en_US
dc.subject.other Treat-to-target en_US
dc.subject.other Value en_US
dc.title Treat-to-target and treat-to-budget in rheumatoid arthritis: Measuring the value of Individual therapeutic interventions en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion https://doi.org/10.1007/s40744-019-00178-3 es_ES
dc.identifier.doi 10.1007/s40744-019-00178-3 es_ES
dc.identifier.publicationfirstpage 473 es_ES
dc.identifier.publicationissue 6 es_ES
dc.identifier.publicationlastpage 477 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Balsa Criado, Alejandro (259517)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record